KJD has been evaluated and reviewed in literature, most extensively in a Nature Reviews Rheumatology paper first published in October 2021. Since then, new evidence has emerged on clinical outcomes, trials, and tissue repair. This mini-review aims to summarize the state of KJD research up until 2024, with a focus on developments from the recent years, and identify knowledge gaps. The authors conclude that KJD shows promise as a joint-preserving treatment for young patients with end-stage knee OA, offering significant and sustained improvements in pain, function, and quality of life while delaying the need for total knee arthroplasty (TKA). Clinical studies have demonstrated its ability to induce cartilage and subchondral bone repair through whole-joint remodeling, though challenges remain, including pin tract infections and variability in treatment response. Ongoing research aims to refine patient selection and a better understanding of KJD’s mechanisms, while large-scale trials like GODIVA are essential for its integration into routine clinical practice. With continued advancements and careful implementation, KJD could become a transformative option for managing knee OA in younger patients.